Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 2016 Annual Results Presentation Stock Code : 0460 0 Disclaimer The sole purpose of this Presentation (the “Presentation”) is to assist the recipient in deciding whether it wishes to proceed with a further investigation of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) and it is not intended to form the basis of any decision to purchase securities, interests or assets in or of the Company. This Presentation does not constitute or contain an offer or invitation or recommendation or solicitation for the sale or purchase of securities, interests or assets in or of the Company and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Any decision to purchase or subscribe for securities in any offering must be made solely on the basis of the information contained in the prospectus or offering circular issued by the company in connection with such offerings. All the information in this Presentation has been provided by the Company and has not been independently verified. No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries as to the appropriateness, accuracy, completeness or reliability of, this Presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed. And no reliance should be placed on the accuracy, fairness, completeness or correctness of the information contained in this Presentation. This Presentation is only being made available to parties who have signed and returned a confidentiality agreement and recipients are therefore bound by the confidentiality agreement in respect of all information contained herein. This Presentation is strictly private and confidential and must not be copied, reproduced, distributed or passed (directly or indirectly, in whole or in part) to any other person at any time, whether for gain or otherwise, without the prior written consent of the Company. By accepting this Presentation, the recipient has agreed to be bound by the limitations contained herein. This Presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By accepting this Presentation the recipient has agreed, upon request and at the recipient’s own costs, to return promptly all material received from the Company (including this Presentation) without retaining any copies. In furnishing this Presentation, the Company and its subsidiaries undertake no obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies therein which may become apparent, and reserve the right, without advance notice, to change the procedure for the sale of securities, interests or assets in or assets of the Company or terminate negotiations at any time prior to the signing of any binding agreement for the sale of securities, interests or assets in or of the Company. This Presentation is directed only at persons which are not “U.S. persons”( “U.S. Persons") as defined under Regulation S of the United States Securities Act of 1933, as amended and, in addition, which are lawfully able to receive this document under the laws of the jurisdictions in which they are located or other applicable laws( “relevant persons”). This document must not be acted on or relied on by persons which are not relevant persons. Any investment or investment activity to which this Presentation relates are available only to relevant persons and will be engaged in only with relevant persons. By accepting this Presentation the recipient represents and warrants that (a) it is lawfully able to receive this document under the laws of the jurisdiction in which it is located or other applicable laws; (b) it is not a U.S. Person, (c) this Presentation is furnished to it outside the United States, and (d) it will not reproduce, publish, disclose, redistribute or transmit this Presentation directly or indirectly, into the United States or to any U.S. Person either within or outside of the recipient’s organisation. The distribution of this Presentation may be restricted by law in certain jurisdictions and persons in whose possession this document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdictions. Any prospective purchaser interested in purchasing securities, interests or assets in or of the Company or evaluating the Company is recommended to seek its own financial and other professional advice. 1 Agenda I Results Overview II Business Review Financial Review III Financial Review IV Future Strategies V Appendix 2 Section 1 Results Overview 3 Performance Overview in 2016 1 ♦ Revenue increased by 0.6% y-o-y to approximately 3,186 million ♦ Profit attributable to owners decreased by 17.2% y-o-y to 1,708 million; excluding the one-off investment income for the same period of last year, it increased by 11.8% y-o-y Maintained market leadership* 2 ♦ 1st in CCV prescription drug market with a market share of 11.86% in terms of hospital purchase; 4th largest pharmaceutical company in China’s hospital market ♦ The Group’s terminal sales growth rate was 8.87%, which was above the industry growth rate of 8.12% in 2016 *Resource: QuintilesIMS data ♦ Phase I clinical trials of innovative patent drug Pirotinib in the US and China progressed 3 smoothly; Phase II clinical trials of innovative patent drug Imigliptin Dihydrochloride have been commenced ♦ Innovative patent drugs Sirotinib and Fadanafil obtained Phase I/II/III clinical trial approvals granted by the CFDA ♦ 47 generic drugs obtained clinical trial approvals issued by the CFDA ♦ Obtained 13 awards for new drug R&D at national, provincial, and municipal levels ♦ Achieved initial success in low-end market penetration while consolidating its business 4 foundation in high-end markets ♦ Established a marketing management center, introduced talents, intensified construction, and further improved marketing & sales capabilities ♦ Directed marketing & sales by academic promotion, identified potential markets in a scientific manner, and achieved efficient market development ♦ 5 After new GMP certification, the production management and quality control system was further optimized ♦ Quality control and production cost control of the manufacturing facilities were further enhanced under the systematic management by the production management & quality control center ♦ Established an audit & compliance center to conduct stricter management over its 6 subsidiaries and to further strengthen compliant operation ♦ Completed a “comprehensive risk management” program, established a risk management system, and achieved standardization of risk management 4 Section 2 Business Review 5 Hospital Market Growth Slows Down but Revived in 2016 Sales in China‘s hospital market / 5 years trend, 2012-2016 100 million/RMB nationwide sales (100 million/RMB) overall growth rate growth rate y-o-y growth rate of Chinese companies growth rate of multinational companies 8000 16.0% 6975 7000 6452 13.4% 6148 6000 5505 11.7% 12.0% 4855 5000 4000 8.1% 8.0% 3000 4.9% 2000 4.0% 1000 0 0.0% 2012 2013 2014 2015 2016 30.0% 27.2% China’s hospital pharmaceutical markets: 2013-2016 moving annual trend (MAT ) ) 25.0% 25.5% 21.6% overall markets Chinese companies multinational companies 20.0% 20.3% 16.7% % (RMB 20.6% 14.0% 14.1% 15.0% 15.7% 13.3% 12.5% 16.5% 13.7% 11.5% rate 13.4% 13.1% 12.8% 10.4% 13.6% 11.7% 8.7% 8.0% 10.0% 12.7% 12.7% 12.8% 12.2% 10.3% 7.0% 11.5% 8.5% 5.1% 5.4% 6.0% 6.1% 8.1% 10.0% 6.6% 6.2% 6.4% 5.0% 7.7% 4.9% 5.5% 7.6% 8.5% Growth 6.9% 5.5% 4.5% 5.6% 0.0% MAT 13Q2 13Q3 13Q4 MAT 14Q2 14Q3 14Q4 MAT 15Q2 15Q3 15Q4 MAT 16Q2 16Q3 16Q4 13Q1 14Q1 15Q1 16Q1 Resource: QuintilesIMS China’s hospital pharmaceutical market report (>=100 beds), 2016Q4 6 Leading Market Position Top 5 Players in China’s CCV Prescription Drug Market in 2016 (Market share) 11.86% 5.43% 4.92% 4.65% 3.51% Sihuan Pfizer SANOFI QILU Shanghai Fosun Top 10 Corporations in China’s Hospital market in 2016 Shares in hospital market Rank Top 10 Corporations In 2016 (%) 1 PFIZER GROUP 2.47% 2 YANGZIJIANG FTY 2.36% 3 ASTRAZENECA GROUP 2.17% 4 Sihuan Pharmaceutical 2.00% 5 QILU PHARM GROUP 1.86% 6 SHANGHAI FUSUN PH 1.63% 7 JS.L.Y.G. HENGRUIK 1.61% 8 SANOFI GROUP 1.58% 9 E LUN 1.57% 10 C.T-TIANQING GP 1.49% Resource: QuintilesIMS 7 Leading Market Position of Main Non-exclusive Products Sihuan’s Generic Name Sihuan’s Market Share and its Top 5 Pharmaceutical Companies and Their Market Brand Name （Total revenue） Ranking in 2016 Share in 2016 Ranked No.2 Sihuan 1. Qilu (山东齐鲁), 59.57% Ganglioside M1 10.46% 2. Sihuan (四环医药), 10.46% GM1 (RMB 6,868 mil) 3. Harbin Medical University (黑龙江哈尔滨医大), 10.37% 4. BJ Saisheng Pharm (北京赛升), 8.58% 5. SC.Taiji Xinan PH (西南药业), 7.27% Ranked No.3 Sihuan 1. BJ Taide (北京泰德), 26.39% 18.30% 2. Hayao Biological (哈药生物), 22.19% Alprostadil Yimaining 3. Sihuan (四环制药), 18.30% (RMB 5,758 mil) 4. Xian Libang Pharm (西安力邦), 14.76% 5. Chongqing Yaoyou (重庆药友), 11.68% Sihuan Ranked No.2 Salviae Miltiorrhizae 23.30% 1.